Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Xoma

450 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 23 »» | Laatste | Omlaag ↓
  1. [verwijderd] 27 juli 2010 15:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    XOMA Limited (NASDAQ:XOMA) has the 4th highest upside potential in this segment of the market. Its upside is 486.9%. Its consensus target price is $1.98 based on the average of all estimates.
  2. gustaaf1e 4 augustus 2010 16:08

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Mooie ontwikkelingen voor XOMA.
    G

    XOMA 052 Designated Orphan Drug by FDA for Treatment of Behcet's Disease

    BERKELEY, Calif., Aug 4, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

    U.S. orphan drug designation is granted by the FDA Office of Orphan Drug Products Development to novel drugs or biologics that may treat a condition affecting fewer than 200,000 persons in the United States. The designation offers a number of potential incentives, which may include, among others, a seven-year period of U.S. marketing exclusivity from the date of marketing authorization, written guidance on the non-clinical and clinical studies needed to obtain marketing approval, and tax credits for certain clinical research.

    In June 2010, XOMA announced positive results from an open-label pilot study of XOMA 052 in Behcet's disease patients who were suffering from vision-threatening disease exacerbations, known as uveitis, despite maximal doses of immunosuppressive medicines. All seven patients who enrolled in the trial displayed rapid reduction of intraocular inflammation and improvement in visual acuity or other ophthalmic measures following a single treatment with XOMA 052. Five patients received a second infusion to blunt a developing exacerbation, and all responded to the second infusion. The drug appeared to be safe, and no drug-related adverse events were reported. Preliminary results were presented at the Annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy and at the International Congress on Behcet's Disease in London in July.

    About Behcet's Disease

    Behcet's (pronounced beh-CHETS) disease is an orphan disease that causes chronic inflammation of the blood vessels, or vasculitis. Major symptoms can affect the neurological, pulmonary, gastrointestinal and cardiovascular systems, and hallmarks of the disease include uveitis, or inflammation of the intraocular tissues of the eye, and painful ulcers in the mouth and on the genitals. Behcet's disease most commonly affects men and women in their twenties, thirties and forties, and it is typically more severe in men. Approximately 16,000 patients in the U.S. are estimated to suffer from Behcet's disease.

    About XOMA 052

    XOMA 052 is a potent monoclonal antibody with the potential to improve the treatment of patients with a wide variety of inflammatory diseases. XOMA 052 binds strongly to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine involved in diseases including Type 2 diabetes, cardiovascular disease, rheumatoid arthritis, gout and auto-inflammatory diseases. IL-1 is a well-validated therapeutic target, with three marketed IL-1 inhibitors that have been used by more than 200,000 patients overall. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation.

    XOMA is conducting two Phase 2 clinical trials of XOMA 052 in patients with Type 2 diabetes and a Phase 2 trial in Type 1 diabetes and has completed a Phase 2 clinical trial in uveitis of Behcet's disease. The Phase 2 trials follow a successful 98 patient Phase 1 program in Type 2 diabetes patients in which XOMA 052 was shown to be well-tolerated, demonstrated evidence of biological activity in diabetes measures and cardiovascular biomarkers, and had a half-life that may provide convenient dosing of once per month or less frequently. The company has also demonstrated the potential for XOMA 052 in in vivo models of atherosclerosis and cardiac remodeling and in an in vitro model using human myeloma, or plasma cell cancer, cells.

  6. [verwijderd] 6 augustus 2010 19:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    tonpa schreef:

    Hoe is het mogelijk, nog verder terug dan af!
    van 3 aug

    -Aug-2010

    Other Events

    Item 8.01. Other Events.
    As previously announced, XOMA Ltd. ("we" or "us") has entered into a Common Share Purchase Agreement dated as of July 23, 2010 (the "Purchase Agreement") with Azimuth Opportunity Ltd. ("Azimuth"), pursuant to which we maintain a $30 million equity line of credit facility with Azimuth.

    On July 26, 2010, we presented Azimuth with a draw down notice pursuant to the Purchase Agreement to sell up to a specified maximum amount of common shares, subject to the limitations set forth in the Purchase Agreement. As permitted by the Purchase Agreement, the parties agreed that the pricing period for this draw down would be five consecutive trading days or such shorter period as determined by Azimuth, so long as Azimuth agreed to purchase the full amount of the draw down request (subject in all events to the limitations set forth in the Purchase Agreement).

    On August 4, 2010, we expect to settle with Azimuth on the sale of 26,393,949 common shares under the terms of the Purchase Agreement and the draw down notice referred to above, for a total purchase price of $7,395,058. We expect to receive net proceeds from the sale of these shares of approximately $7,235,058 after deducting our estimated offering expenses and placement agent fees. As of August 2, 2010, we had 266,605,553 common shares outstanding.

    The foregoing descriptions are qualified in their entirety by reference to the Purchase Agreement, a copy of which is incorporated by reference as Exhibit 10.1 hereto.

    dat is .28 cent per aandeel
    aangezien ze kosten er al hadden afgetrokken, evt .30 per aandeel aan 26mln nieuwe aandelen
  7. [verwijderd] 18 augustus 2010 15:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bullish movements stocks at NASDAQ: (PCBC, XOMA, JOEZ, CPST, THQI)

    Dear PSL members,

    Bullish movements stocks at NASDAQ: (PCBC, XOMA, JOEZ, CPST, THQI)

    Pacific Capital Bancorp (NASDAQ: PCBC) surged by 20.84% to close at $1.06. It touched the day low of $0.85 with overall traded volume of 3.51 million shares. Pacific Capital Bancorp (PCB) is a community bank holding company providing full service banking, including all aspects of consumer and commercial lending, trust and investment advisory services and other consumer and business banking products through its subsidiaries’ retail branches, commercial and wealth management centers and other distribution channels to consumers and businesses primarily located in the central coast of California.

    XOMA Limited (NASDAQ: XOMA) jumped up by 2.22% and closed at 0.28. It touched the day high of $0.29 whereas total traded volume stood at 3.30 million shares for the day. XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases.

    Joe’s Jeans Inc. (NASDAQ: JOEZ) closed at $2.09 after moving up by 14.21% with traded volume of 2.24 million shares in the last trading session. Joe’s Jeans Inc. (Joe’s) is engaged in designing, developing and marketing of its Joe’s products, which include denim jeans, related casual wear and accessories.

    Capstone Turbine Corporation (NASDAQ: CPST) touched the day high of $0.73 and low of $0.71. It reported the gain of 4.29% and closed at $0.73 whereas overall traded volume stood at 2.07 million shares. Capstone Turbine Corporation (Capstone) develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications, including cogeneration (combined heat and power (CHP), integrated combined heat and power (ICHP), and combined cooling, heat and power (CCHP)), resource recovery and secure power.

    THQ Inc. (NASDAQ: THQI) increased by 5.21% to close at $3.84 with total traded volume of 1.99 million shares in the last trading session. THQ Inc. (THQ) is a worldwide developer and publisher of interactive entertainment software for all game systems, including home video game consoles, such as the Microsoft Xbox 360 (Xbox 360), Nintendo Wii (Wii), Sony PlayStation 3 (PS3) and Sony PlayStation 2 (PS2); handheld platforms, such as the Nintendo DS and DSi (collectively referred to as DS), and Sony PlayStation Portable (PSP); wireless devices, including the iPhone, iTouch and iPad, and personal computers (PCs), including games played online.

    ***********************

    PennyStockLive.com has indispensible trading suggestions for all types of investors, whether you are a novice trader or an expert.

    We provide Buy, Sell, and Stop Loss trading figures that help investors make wise unemotional decisions regarding each of our trade ideas.
    Real-Time Alerts
    Receive alerts for companies from NYSE, NASDAQ, AMEX, and OTCBB markets.
    Our staff sifts through more than 100 companies each week to find the best stock trading opportunities.
    Industry Leading Charts that help investors see our investment ideas regarding each company.
    News Alerts provides subscribers with incoming news that can have a significant impact on their investments.
    Quick Customer Service
    No Contracts, No Commitments, No Risk, No Catches, No Hidden Fees.
    We dare you to compare. Our services are unlike any others.
    To subscribe to our free newsletter services, click HERE.

    ************************

    Happy trading,

    PSL staff, www.PennyStockLive.com
  9. Cybertom 25 augustus 2010 00:02

    • Cybertom

      Lid sinds: 02 jul 2003

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 2063

      Gegeven: 289

    •    Aantal posts: 3.752

    Net voor de reverse stock split had ik 250k aandelen aangeschaft. Die dag werd nabeurs de rss aangekondigd. Sindsdien kan ik nog steeds niet mijn aandelen (zo'n 16k) verkopen omdat ABN/Amro de conversie nog niet heeft kunnen verwerken. Inmiddels is de koers meer dan 30% gezakt. Hebben meer mensen dit meegemaakt, bij Xoma of een ander fonds? Uiteraard heb ik meteen contact opgenomen met de bank, maar die zeggen dat ze ook maar afhankelijk zijn van de gegevens vanuit Amerika en voor mijn gevoel willen ze hun verantwoordelijk ontlopen. Reacties zijn zeer welkom, thanks!
  12. gustaaf1e 4 januari 2011 19:15

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    Weer goed nieuws voor XOMA.
    Mooie groeier de komende tijd.
    G

    RTTNews) - XOMA Ltd. (XOMA), a developer and manufacturer of therapeutic antibodies, Tuesday announced the signing of a regional agreement with France's privately-held pharmaceutical company Les Laboratoires Servier to jointly develop and commercialize XOMA 052, an anti-inflammatory drug candidate of XOMA, in multiple indications.

    XOMA 052 is designed to inhibit the pro-inflammatory cytokine interleukin-1 beta that is believed to be a primary trigger of pathologic inflammation in multiple diseases.

    Under the deal, XOMA will receive approximately $35 million upfront payment, up to approximately $470 million in milestone payments and tiered royalties up to a mid-teens percentage rate.

    XOMA will be responsible for the manufacturing of XOMA 052 throughout clinical development and launch and anticipates being a long-term manufacturer.

    Servier will fund the first $50 million of XOMA 052 development expenses and 50% of further expenses for the Behcet's uveitis indication. In 2011, XOMA 052 is expected to advance into Phase 3 development in Behcet's uveitis, an ophthalmic inflammatory condition that often leads to vision-threatening complications including blindness. Servier will also fund development for diabetes and cardiovascular disease indications in exchange for worldwide rights.

    Further, XOMA stated that it retains an option to reacquire the development and commercialization rights to the diabetes and cardiovascular indications in the U.S. and Japan by paying an option fee and partial reimbursement of incurred development expenses. If XOMA reacquires these rights, it has the ability to license them to one or more third parties.

    XOMA also said that the companies expect to hold discussions with multiple regulatory agencies in 2011 to initiate Phase 3 studies of XOMA 052 in Behcet's uveitis. XOMA 052 has already received orphan drug designations for Behcet's disease from regulators in the U.S. and European Union.

    XOMA also stated that it expects to release results from two ongoing Phase 2 studies in patients with Type 2 diabetes in the first quarter of 2011.

    For comments and feedback: contact editorial@rttnews.com

  15. gustaaf1e 12 februari 2012 13:00

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656


    February 6, 2012

    XOMA to Present at 14th Annual BIO CEO & Investor Conference

    BERKELEY, Calif., Feb. 6, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced John Varian, Chief Executive Officer, will present a company overview at the 14th Annual BIO CEO & Investor Conference on February 13, 2012, at 9:30 a.m. EST in New York City.

    A live webcast of the presentation will be available via the Investors tab at the XOMA website, www.xoma.com, and an archived version will be available on the XOMA website for 30 days following the presentation
  16. gustaaf1e 6 maart 2012 18:40

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656

    RTTNews.com) - XOMA Corp. (XOMA) said Tuesday that it has priced about 29.67 million shares of its common stock and accompanying warrants to purchase one half of a share of common stock for each share purchased at a price to the public of $1.32.

    The warrants are exercisable at an exercise price of $1.76 per share beginning on the date of issuance and will expire on the fifth anniversary of the date of issuance. All of the shares and warrants in the offering are to be sold by XOMA.

    XOMA anticipates that its aggregate net proceeds from the offering will be about $36.2 million after deducting the underwriting discount and estimated offering expenses payable by XOMA.

    The offering is expected to close on or about March 9.

    G
  18. gustaaf1e 27 juni 2012 18:22

    • gustaaf1e

      Lid sinds: 01 jan 2000

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 54

      Gegeven: 1

    •    Aantal posts: 1.656



    XOMA Initiates Phase 3 Gevokizumab Trial in Patients With Non-Infectious Uveitis and Phase 2 Gevokizumab Trial in Patients With Erosive Osteoarthritis

    BERKELEY, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced it has opened enrollment in two clinical trials to determine gevokizumab's potential to treat interleukin-1 beta-mediated inflammatory diseases. The first trial is XOMA's global Phase 3 study investigating the ability of gevokizumab to reduce the signs and symptoms, including vitreous haze, in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The second trial is a Phase 2 study to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with erosive osteoarthritis of the hand. Patients currently are being screened in both trials.

    "Today represents an historic milestone for XOMA, as we launch the first global Phase 3 program for a XOMA-created product to which we retain U.S. commercial rights," stated John Varian, Chief Executive Officer of XOMA. "Our clinical and regulatory teams have worked diligently with their colleagues from Servier to design the gevokizumab NIU trial to meet the requirements of regulatory agencies, including the FDA, in this indication."

    In this study, titled A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis, the Company intends to enroll patients with active non-infectious intermediate, posterior, or pan-uveitis with a vitreous haze score equal to or greater than 2+ on the Standardization of Uveitis Nomenclature (SUN) / National Eye Institute (NEI) scale in at least one eye. They will be randomized to receive either one of two doses of gevokizumab or placebo. The study's primary endpoint is the proportion of patients demonstrating a significant reduction in vitreous haze score on Day 56. The study also will assess the effect of gevokizumab on additional endpoints, including response rates at other time points and changes from baseline in visual acuity.

    Paul Rubin, M.D., XOMA's Senior Vice President of Research and Development and Chief Medical Officer, stated, "As preclinical and clinical data have shown that IL-1 beta is an important contributor to the inflammation seen in uveitis, we believe gevokizumab's ability to potently inhibit IL-1 beta signaling could be relevant in controlling this inflammation, as well as the inflammation associated with other conditions. Because of this, we established a proof-of-concept program in November 2011 to lead us to additional indications for this antibody. Included in this program is the ongoing trial in moderate to severe acne vulgaris from which we anticipate top-line data by year end. Today, we opened enrollment in the second POC indication, erosive osteoarthritis of the hand, which we believe will complete enrollment sometime around the end of 2012."

    XOMA's Phase 2 proof-of-concept study of gevokizumab in active inflammatory, erosive osteoarthritis of the hand is designed to enroll approximately 90 patients who will be randomized to receive gevokizumab or placebo. The study is designed and powered to detect a significant improvement from baseline versus placebo in the mean Australian/Canadian Hand Osteoarthritis Index (AUSCAN™) pain score in the target hand at three months. The study also will capture multiple outcome measures including pain, stiffness, physical function, radiographic and MRI changes, as well as changes in C-reactive protein and concomitant acetaminophen use.


    G
450 Posts
Pagina: «« 1 ... 12 13 14 15 16 ... 23 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.482
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.201
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.528
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.650
Aedifica 3 901
Aegon 3.258 322.664
AFC Ajax 538 7.086
Affimed NV 2 6.288
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.293
Air France - KLM 1.025 34.998
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.333
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.741
AMG 971 133.088
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.936
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.579
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.082
ASML 1.766 106.062
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 07 februari

    1. Aperam Q4-cijfers
    2. Orange Belgium Q4-cijfers
    3. Crédit Agricole Q4-cijfers (Fra)
    4. TotalEnergies Q4-cijfers (Fra)
    5. Novo Nordisk Q4-cijfers (Dee)
    6. Industriële productie december (Dld)
    7. Handelsbalans december (Dld)
    8. Harley-Davidson Q4-cijfers (VS)
    9. Banengroei en werkloosheid januari (VS) Banengroei: 170K, werkloosheid: 4,1%, uurlonen: +3,8% YoY volitaliteit verwacht
    10. Consumentenvertrouwen (Universiteit v Michigan) februari vlpg (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda